Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Tofacitinib
Treatment for Rheumatoid arthritis
Typical Dosage: 5 mg twice daily or 11 mg extended-release once daily (oral)
Effectiveness
78%
Safety Score
38%
Clinical Trials
105
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg twice daily or 11 mg extended-release once daily (oral)
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$1,800
Side Effect Mgmt:$1,200
Total Annual:$53,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$135,000/QALY
QALYs Gained
1.3
Outcome-Based Costs
Cost per Responder
$88,333.33
Cost per Remission
$212,000
Comparison vs Methotrexate
Cost Difference
+$51,400/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Tofacitinib Outcomes
for Rheumatoid arthritis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+60%
Remission Rate
+25%
Common Side Effects
Upper respiratory tract infections
+20%
Headache
+12%
Diarrhea
+8%
Herpes zoster
+5%
Serious infections
+4%
Venous thromboembolism (VTE)
+1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Tofacitinib in Rheumatoid arthritis
Advanced Therapeutics in Rheumatoid Arthritis (RA)
NCT03976245RECRUITINGPHASE4
144 participants
INTERVENTIONAL
London, Canada
Started: Mar 1, 2020
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT06020144ACTIVE NOT RECRUITINGPHASE3
459 participants
INTERVENTIONAL
Beijing, China
Started: Nov 15, 2023
Completed Clinical Trials
13 completed trials for Tofacitinib in Rheumatoid arthritis
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
NCT02281552COMPLETEDPHASE3
209 participants
INTERVENTIONAL
Nagoya, Japan +35 more
Started: Nov 18, 2014
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
NCT03981900COMPLETED
314 participants
OBSERVATIONAL
Arras, France +65 more
Started: Jan 4, 2019
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
NCT01262118COMPLETEDPHASE1
69 participants
INTERVENTIONAL
Anniston, United States +10 more
Started: May 1, 2011
Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project
NCT04175886COMPLETED
10 participants
OBSERVATIONAL
Lille, France
Started: Feb 25, 2020
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
NCT03387423COMPLETED
1.46K participants
OBSERVATIONAL
Düsseldorf, Germany +90 more
Started: Nov 2, 2017
An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective
NCT02566967COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Aventura, United States
Started: May 1, 2015
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
NCT04721821COMPLETED
7.81K participants
OBSERVATIONAL
New York, United States
Started: Jan 22, 2021
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
NCT02831855COMPLETEDPHASE4
694 participants
INTERVENTIONAL
Huntsville, United States +135 more
Started: Sep 1, 2016
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
NCT02092467COMPLETEDPHASE4
4.37K participants
INTERVENTIONAL
Birmingham, United States +344 more
Started: Mar 14, 2014
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate
NCT02147587COMPLETEDPHASE2
112 participants
INTERVENTIONAL
Jonesboro, United States +35 more
Started: Jun 1, 2014
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept
NCT04529876COMPLETED
29.5K participants
OBSERVATIONAL
Boston, United States
Started: Aug 17, 2020
The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
NCT04928066COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Jinan, China
Started: Mar 1, 2020
Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers
NCT03868072COMPLETEDPHASE1
40 participants
INTERVENTIONAL
Osong, South Korea
Started: Feb 22, 2019
Showing 20 of 107 total trials